MADABHAVI I, PATEL A, MODI G, ANAND A, PANCHAL H, PARIKH SMADABHAVI I, PATEL A, MODI G, ANAND A, PANCHAL H, PARIKH S
044440 MADABHAVI I, PATEL A, MODI G, ANAND A, PANCHAL H, PARIKH SMADABHAVI I, PATEL A, MODI G, ANAND A, PANCHAL H, PARIKH S (Medical and Pediatric Oncology Dep, Gujarat Cancer Research Institute, Ahmedabad, Gujarat, Email: irappamadabhavi@ gmail.com) : Pediatric chronic myeloid leukemia: A single‑center experience. J Can Res Ther 2020, 16(1), 110-5.
The rationale of this study is to reveal the statistics of pediatric chronic myeloid leukemia (CML) patients. It is a retrospective analysis conducted to assess pediatric CML data from January 1998 to December 2014. There are 65 (3.2 %) pediatric CML patients out of entire 2008 patients of CML. Data were analyzed regarding epidemiological characteristics, clinical presentations, response and side effects of imatinib, event‑free survival, and overall survival of the pediatric CML patients. The median age of diagnosis was 11.84 years, and 76.9 % patients were male and 23.07 % patients were female. Sixty(92.3 %) patients were in CML‑chronic phase, 3 (4.6 %) patients in CML‑accelerated phase, and 2 (3.07 %) patients in CML‑blastic crisis. Most common initial symptoms and signs are weakness (60.0 %), abdominal pain (55.38 %), splenomegaly (100 %), and hepatomegaly (86.5 %). 67.3 % of patients have white blood counts <100 × 109 /L and 92.3 % had platelets >150 × 109 /L. In the initial months of 2002, imatinib was available and utilized in 54 patients. Of 54 patients, complete hematological response at 3months, partial cytogenetic response at 6 months, complete cytogenetic response at 12 months, and major molecular response (MMR) at 18 months were 77.77 %, 59.2 %, 48.14 %, and 40.74 %, respectively. MMR at 36 months was 62.96 % (n = 34). Most common imatinib‑related side effects are gastrointestinal upset and myelosuppression. Pediatric CML in India is comparable with Western countries regarding epidemiological characteristic, clinical presentations, and tolerance of imatinib. As there is a paucity of universal literature regarding pediatric CML (especially data from Southeast Asian region), this article may fill up that space.
1 table, 40 ref